Opiorphin Levels in Fluids of Burning Mouth Syndrome Patients (OPIODYN)
CompletedNot applicableNCT02686359
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
If epidemiological studies indicate relatively low prevalence reported in the general population, idiopathic burning mouth syndrome (BMS) is a common condition among certain groups of the population: 30% of menopausal women experience oral burning to varying degrees . Despite significant progress made in recent years, in understanding the physiopathogeny, treatment options remain limited and disappointing,resulting in an impairment of the quality of life. Given the chronic nature of idiopathic burning mouth syndrome, the need to identify the causes and effective treatment modalities for subjects suffering is essential.
Study details
- Official title
- Research of a Biological Marker for Chronic Orofacial Pain: Dosage of Opiorphin in Patients With Burning Mouth Syndrome
- Conditions
- Burning Mouth Syndrome
- Interventions
- Biological: sample
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Collaborators
- Institut Pasteur
- Start date
- 2011-07
- Primary completion
- 2012-12
- Sex
- All
- Age range
- from 18 Years to 80 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Clinical diagnosis of Burning Mouth Syndrome * Age between 18 and 80 years * Sensation of pain in the oral mucosa, meeting the diagnostic criteria for BMS (Bergdahl and Anneroth, 1993, Scala 2003) * Signature of informed consent Healthy volunteers * Age between 18 and 80 years * Patient age (+/- 5 years), sex and hormonal status (menopause or not for women) matched with a Burning Mouth Syndrome patient * Signature of informed consent Exclusion Criteria: * Dental or periodontal pain during the month before the visit * General pathology likely to cause mouth pain (diabetes, lupus, shingles, gastric reflux, allergies ...) * Chronic Orofacial pain other than Burning Mouth Syndrome * Treatment with a molecule able to induce oral burning sensations (anti-VEGF, neuroleptics, IEC angiotensin II ...) * Participation concomitantly in biomedical research * No affiliation to a social protection system * Taste disorder other than a dysgeusia linked to Burning Mouth Syndrome * Inability to understand the information note and sign the informed consent
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02686359